Mainstay confirms its continued eligibility to the PEA-PME
Dublin, Ireland: 24 January 2017 - Mainstay Medical International plc (listed on Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE) confirms today its continued eligibility to the PEA-PME (French equity savings plan for financing SMEs), in accordance with Decree n° 2014-283 applicable since 4 March 2014 and reflecting the application of Article 70 of 2014 finance law (n° 2013-1278 dated 29 December 2013) which set up the conditions of companies' eligibility for the PEA-PME as follows:
- fewer than 5,000 employees, and
- annual revenues of less than € 1.5 billion, or
- a balance-sheet total of less than € 2.0 billion.
Mainstay Medical is an Irish medical device company with operations in Ireland, Australia, Germany and the United States. The Company is focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain ("CLBP").
More info on Mainstay Medical's website.
Next > Neurosurgeons from Germany and USA report on their clinical experience of using Nexstim NBS system
Previous > EpiGaN is Named among the 2017 Global Cleantech 100